G

    GT Biopharma Inc (GTBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.29
    -0.01 (-4.67%)

    Market Cap: $13.53M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(12/23)
    Avg Surprise
    -479.03%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.08+20.0%
    60d ago$-0.08+20.0%
    30d ago$-0.08+20.0%
    7d ago$-0.08+20.0%
    Current$-0.10
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.17 - $-0.17
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.17---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.12$-0.08-50.00%Miss+78.2%
    Mar 26
    		$-0.11$-0.08-37.50%Miss+85.5%
    Dec 25
    		$-4.84$-0.22-2100.00%Miss-191.6%
    Sep 25
    		$-0.83$-0.38-118.42%Miss+45.8%
    Jun 25
    		$-0.55$-0.68+19.12%Beat+74.6%
    Mar 25
    		$-0.76$-0.64-18.75%Miss+53.7%
    Dec 24
    		$-1.66$-1.55-7.10%Miss+24.2%
    Sep 24
    		$-1.53$-2.70+43.33%Beat+28.2%
    Jun 24
    		$-2.17$-2.70+19.74%Beat+14.7%
    Mar 24
    		$-1.64$-2.70+39.26%Beat+42.5%
    Dec 23
    		$-2.19$-2.70+18.89%Beat-1116.7%
    Sep 23
    		$-2.13$-3.30+35.45%Beat+67.8%
    Jun 23
    		$-2.54$-3.60+29.44%Beat+11.2%
    Mar 23
    		$-2.85$-4.35+34.48%Beat-1576.5%
    Dec 22
    		$-0.18$-0.17-5.88%Miss+98.9%
    Sep 22
    		$-6.61$-3.30-100.30%Miss-16.2%
    Jun 22
    		$-2.86$-5.40+47.04%Beat+27.0%
    Mar 22
    		$-0.17$-0.31+45.16%Beat+99.7%
    Dec 21
    		$-15.76$-6.30-150.16%Miss-364.9%
    Sep 21
    		$-5.69$-7.05+19.29%Beat-14125.0%
    Jun 21
    		$-3.92$-7.65+48.76%Beat-3166.7%
    Mar 21
    		$-54.90$-9.90-454.55%Miss-274400.0%
    Dec 20
    		$-3.39$-0.04-8375.00%Miss-16850.0%
    Sep 20
    		$-0.04N/AN/ABeat+92.2%
    Jun 20
    		$-0.12N/AN/ABeat-140.0%
    Mar 20
    		$-0.02N/AN/ABeat+77.8%
    Dec 19
    		$-0.02N/AN/ABeat+75.0%
    Sep 19
    		$-0.51N/AN/ABeat+89.1%
    Jun 19
    		$-0.05N/AN/ABeat+72.2%
    Mar 19
    		$-0.09N/AN/ABeat+55.0%
    Dec 18
    		$-0.08N/AN/ABeat+33.3%
    Sep 18
    		$-4.70N/AN/ABeat+42.3%
    Jun 18
    		$-0.18N/AN/ABeat+99.9%
    Mar 18
    		$-0.20N/AN/ABeat+99.8%
    Dec 17
    		$-0.12N/AN/ABeat+100.0%
    Sep 17
    		$-8.15N/AN/ABeat+72.3%
    Jun 17
    		$-138.55N/AN/ABeat-
    Mar 17
    		$-87.40N/AN/ABeat-
    Dec 16
    		$-448.21N/AN/ABeat-
    Sep 16
    		$-29.41N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDA-0.09x
    Price/FCF-0.77xFCF Yield-129.93%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-113.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.61xQuick Ratio2.61x
    Trading Statistics
    Beta0.90Avg Volume414.28K
    52-Week High$1.3752-Week Low$0.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.29
    SMA 20$0.30
    SMA 50$0.36
    SMA 200$0.49
    EMA 10$0.29
    EMA 20$0.30
    EMA 50$0.34
    EMA 200$0.58

    MACD

    Line: -0.02Signal: -0.02Hist: 0.00

    ADX

    ADX: 28.9+DI: 16.8-DI: 23.2

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down64.0
    PSAR$0.27

    Bollinger Bands

    Upper Band$0.33
    Lower Band$0.27
    %B Position1886%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    40.8

    Momentum Oscillators

    Stoch %K43.4
    Stoch %D43.2
    Williams %R-67.0
    ROC (10d)0.4%
    Momentum0.00
    CCI (20d)-26.6
    MFI (14d)40.7

    Volatility Measures

    ATR (14d)$0.02(8.0%)
    StdDev (20d)0.01
    Hist Vol59.2%(High)

    Volume Flow

    VWAP$0.30
    OBV102.6M
    AD Line6.3M
    CMF (20d)-0.216

    Volume Metrics

    Avg Vol (20d)414.0K
    Vol Ratio0.8x
    VWMA (20d)$0.30

    Pivot Points

    R3$0.32
    R2$0.32
    R1$0.31
    Pivot Point$0.30
    S1$0.30
    S2$0.29
    S3$0.28

    Advanced Oscillators

    TSI-17.90
    Ultimate Osc34.3
    KST-163.56

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$4.51M$2.85M$5.59M$3.38M$1.51M$1.93M$3.76M$3.60M$3.91M$3.09M$3.17M$3.12M
    R&D$1.05M$413,000$1.38M$634,000$363,000$1.10M$1.93M$1.31M$1.78M$777,000$1.36M$1.36M
    SG&A$3.46M$2.44M$4.22M$2.75M$1.15M$833,000$1.83M$2.30M$2.12M$2.31M$1.81M$1.76M
    Operating Income$-4,512,000$-2,848,000$-5,595,000$-3,382,000$-1,513,000$-1,932,000$-3,763,000$-3,604,000$-3,906,000$-3,091,000$-3,168,000$-3,122,000
    Interest Income$58,000$67,000$17,000$36,000$38,000$32,000$59,000$96,000$105,000$142,000$180,000$216,000
    Interest Expense$64,000$63,000$1.13M$0$0$-998,000$12,000$0$0$0$1,000$0
    Income Before Tax$-4,518,000$-2,833,000$-23,031,000$8.30M$-30,169,000$-776,000$-3,775,000$-3,411,000$-3,710,000$-2,266,000$-2,962,000$-2,416,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,518,000$-2,833,000$-23,031,000$8.30M$-30,169,000$-776,000$-3,775,000$-3,411,000$-3,710,000$-2,266,000$-2,962,000$-2,416,000
    EBITDA$-4,512,000$-2,837,000$-21,923,000$8.26M$-30,207,000$-1,806,000$-3,834,000$-3,507,000$-3,815,000$-2,408,000$-3,142,000$-2,632,000
    EBIT$-4,512,000$-2,837,000$-21,923,000$8.26M$-30,207,000$-1,806,000$-3,834,000$-3,507,000$-3,815,000$-2,408,000$-3,142,000$-2,632,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GTBP

    News

    GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes

    GT Biopharma shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, and a reduction in authorized shares to 25,000,000 common and 1,500,000 preferred shares. They also approved a 3,500,000-share increase to the 2022 Omnibus Incentive Plan and an evergreen provision for automatic annual increases. These decisions were made at the Annual Meeting held on August 14, 2026, with a quorum of 52.68% of eligible common shares represented.

    Stock Titan•8/14/26•
    Neutral

    GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

    GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened to $4.5 million due to increased R&D and SG&A expenses. The company's $5.1 million cash balance is projected to fund operations through Q4 2026, and it continues to advance its TriKE platform with two Phase 1 clinical trials.

    scanx.trade•8/14/26•
    Somewhat-Bearish

    GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026

    GT Biopharma (GTBP) reported a narrowed net loss of $4.5 million in Q2 2026, a significant improvement from $30.2 million year-over-year, attributed to the absence of a prior non-recurring liability. The company is advancing two TriKE® candidates in Phase 1 trials, with updates anticipated in the second half of 2026. GT Biopharma projects its cash runway to extend through the fourth quarter of 2026.

    TradingView•8/14/26•
    Somewhat-Bullish

    GT Biopharma Reports Second Quarter 2026 Financial Results

    GT Biopharma announced its second quarter 2026 financial results, highlighting ongoing Phase 1 trials for two TriKE® candidates, GTB-3650 and GTB-5550, with updates expected in the second half of 2026. The company reported a cash balance of $5.1 million, sufficient to fund operations through Q4 2026, and an increased net loss of $4.5 million primarily due to higher R&D and SG&A expenses. GT Biopharma is also integrating AI into its discovery process for new development candidates.

    GlobeNewswire•8/14/26•
    Somewhat-Bullish

    GT Biopharma Reports Second Quarter 2026 Financial Results

    GT Biopharma, Inc. announced its second-quarter 2026 financial results, highlighting ongoing Phase 1 trials for its TriKE® candidates, GTB-3650 for leukemia and GTB-5550 for solid tumors, with updates expected in the second half of 2026. The company reported a cash balance of approximately $5.1 million as of June 30, 2026, projected to fund operations through Q4 2026, and is actively integrating AI into its discovery process for new development candidates.

    Yahoo! Finance Canada•8/14/26•
    Somewhat-Bullish

    Frequently Asked Questions About GTBP

    Does GTBP pay dividends?
    GT Biopharma Inc (GTBP) does not currently pay a regular dividend.
    What is GTBP's market cap?
    GT Biopharma Inc (GTBP) has a market capitalization of $13.53M with a current stock price of $0.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In